Compare 10X Genomics Inc (TXG) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs TeraWulf Inc — how do they compare? 10X Genomics Inc trades at $79.21 (market cap $10.07B), while TeraWulf Inc trades at $13.87 (market cap $6.81B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and TeraWulf Inc for 17 Days on average.
| TXG | WULF | |
|---|---|---|
Market Cap | $10.07B | $6.81B |
Volume | 5,657,286 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $97.74 | $28.98 |
52-Week Low | $11.48 | $10.99 |
Typical Hold Time | 92 Days | 17 Days |
Enterprise Value | $9.59B | $9.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
WULF trades at $14.40, down 3.81% on the day, with a bearish technical signal from moving averages and oscillators showing mixed signals. The company reported a net loss of -$661.42M in 2025, with revenue of $168.46M, and has missed earnings expectations in recent quarters. Analyst consensus remains strongly bullish with a $34.92 price target, supported by positive news on AI data center leasing trends.
The outlook for WULF hinges on its pivot to AI data center hosting, offering growth potential, but significant risks persist from deep losses, negative margins, and high debt. Investors should weigh analyst optimism against fundamental weaknesses and volatile cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
